First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants

Data de publicação: 01/12/2022 Data Ahead of Print: 01/08/2022

Autores da FMUP

Carla Isabel Gonçalves De Oliveira

Autor

Participantes de fora da FMUP

Coudert, M
Drouet, Y
Delhomelle, H
Svrcek, M
Benusiglio, PR
Coulet, F
Clark, DF
Katona, BW
van Hest, LP
van der Kolk, LE
Cats, A
van Dieren, JM
Nehoray, B
Slavin, T
Spier, I
Hüneburg, R
Lobo, S
Boussemart, L
Masson, L
Chiesa, J
Schwartz, M
Buecher, B
Golmard, L
Bouvier, AM
Bonadona, V
Stoppa-Lyonnet, D
Lasset, C
Colas, C

Abstract

Background Pathogenic variants (PV) of CTNNA1 are found in families fulfilling criteria for hereditary diffuse gastric cancer (HDGC) but no risk estimates were available until now. The aim of this study is to evaluate diffuse gastric cancer (DGC) risks for carriers of germline CTNNA1 PV. Methods Data from published CTNNA1 families were updated and new families were identified through international collaborations. The cumulative risk of DGC by age for PV carriers was estimated with the genotype restricted likelihood (GRL) method, taking into account non-genotyped individuals and conditioning on all observed phenotypes and genotypes of the index case to obtain unbiased estimates. A non-parametric (NP) and the Weibull functions were used to model the shape of penetrance function with the GRL. Kaplan-Meier incidence curve and standardised incidence ratios were also computed. A 'leave-one-out' strategy was used to evaluate estimate uncertainty. Results Thirteen families with 46 carriers of PV were included. The cumulative risks of DGC at 80 years for carriers of CTNNA1 PV are 49% and 57%, respectively with the Weibull GRL and NP GRL methods. Risk ratios to population incidence reach particularly high values at early ages and decrease with age. At 40 years, they are equal to 65 and 833, respectively with the Weibull GRL and NP GRL. Conclusion This is the largest series of CTNNA1 families that provides the first risk estimates of GC. These data will help to improve management and surveillance for these patients and support inclusion of CTNNA1 in germline testing panels.